Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα+γ Agonists
Despite clinical promise, dual-acting activators of PPARα and γ (here termed PPARα+γ agonists) have experienced high attrition rates in preclinical and early clinical development, due to toxicity. In some cases, discontinuation was due to carcinogenic effect in the rat urothelium, the epithelial lay...
Saved in:
| Main Authors: | Martin B. Oleksiewicz, Jennifer Southgate, Lars Iversen, Frederikke L. Egerod |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2008/103167 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antidiabetic Effect of Dihydrobetulonic Acid Derivatives as Pparα/γ Agonists
by: Mikhail V. Khvostov, et al.
Published: (2024-12-01) -
PPARγ Agonists: Blood Pressure and Edema
by: Bonnie L. Blazer-Yost
Published: (2010-01-01) -
PPARα/γ-Independent Effects of PPARα/γ Ligands on Cysteinyl Leukotriene Production in Mast Cells
by: Masamichi Yamashita
Published: (2008-01-01) -
Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia
by: O. Samuelsson, et al.
Published: (2013-01-01) -
Deciphering the Roles of Thiazolidinediones and PPARγ in Bladder Cancer
by: Melody Chiu, et al.
Published: (2017-01-01)